Company Filing History:
Years Active: 2011
Title: Colette Cote: Innovator in Genetic Therapy
Introduction
Colette Cote is a distinguished inventor based in Gaithersburg, MD (US). She has made significant contributions to the field of genetic therapy, particularly in addressing genetic defects associated with alpha-1-antitrypsin deficiency. Her innovative work has the potential to impact the lives of many individuals suffering from this condition.
Latest Patents
Colette Cote holds a patent for her invention titled "Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing." This invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule. This interaction mediates a trans-splicing reaction that results in the generation of a novel chimeric RNA molecule. The PTMs are genetically engineered to correct SERPINA1 genetic defects responsible for AAT deficiency. Additionally, the PTMs may yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs, aimed at reducing the accumulation of toxic AAT protein in liver cells. The methods and compositions can be utilized in gene therapy for correcting SERPINA1 disorders such as AAT deficiency.
Career Highlights
Colette Cote is currently associated with Virxsys Corporation, where she continues to advance her research and innovations in genetic therapy. Her work is characterized by a commitment to developing effective solutions for genetic disorders.
Collaborations
Colette has collaborated with notable colleagues, including Madaiah Puttaraju and Edward Otto, who have contributed to her research endeavors.
Conclusion
Colette Cote's innovative work in genetic therapy exemplifies the potential of scientific advancements to address critical health issues. Her contributions are paving the way for future developments in the treatment of genetic disorders.